We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PTKFF market cap is 3.47B. The company's latest EPS is IDR 70.0593 and P/E is 0.00.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Total Revenue | 23.11T | 26.26T | 28.93T | 30.45T | 32.63T |
| Operating Income | 3.5T | 4.49T | 4.49T | 3.9T | 4.78T |
| Net Income | 2.73T | 3.18T | 3.38T | 2.77T | 3.24T |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Total Assets | 22.56T | 25.67T | 27.24T | 27.06T | 29.43T |
| Total Liabilities | 4.29T | 4.4T | 5.14T | 3.94T | 4.84T |
| Total Equity | 18.28T | 21.27T | 22.1T | 23.12T | 24.59T |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Operating | 4.22T | 2.83T | 1.27T | 2.91T | 4.79T |
| Investing | -951.22B | -1.06T | -1.37T | -1.14T | -1.25T |
| Financing | -1.1T | -745.18B | -2.41T | -2.44T | -2.09T |
| Market Cap | 3.47B |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | 693,640,479.36% |
| Shares Outstanding | 46.26B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -16.56% |
| 52 Week High | 0.1135 |
| 52 Week Low | 0.06495 |
| Spread (Intraday) | 0.04 (42.62%) |
| Company Name | PT Kalbe Farma TBK (PK) |
| Address |
kalbe building jakarta, java 10510 |
| Website | https://www.kalbe.co.id |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
